104 results on '"Schanz J"'
Search Results
2. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
- Author
-
Della Porta, M G, Tuechler, H, Malcovati, L, Schanz, J, Sanz, G, Garcia-Manero, G, Solé, F, Bennett, J M, Bowen, D, Fenaux, P, Dreyfus, F, Kantarjian, H, Kuendgen, A, Levis, A, Cermak, J, Fonatsch, C, Le Beau, M M, Slovak, M L, Krieger, O, Luebbert, M, Maciejewski, J, Magalhaes, S M M, Miyazaki, Y, Pfeilstöcker, M, Sekeres, M A, Sperr, W R, Stauder, R, Tauro, S, Valent, P, Vallespi, T, van de Loosdrecht, A A, Germing, U, Haase, D, Greenberg, P L, and Cazzola, M
- Published
- 2015
- Full Text
- View/download PDF
3. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
- Author
-
Porta, Della MG, Tuechler, H, Malcovati, L, Schanz, J, Sanz, G, Garcia-Manero, G, Solé, F, Bennett, J M, Bowen, D, Fenaux, P, Dreyfus, F, Kantarjian, H, Kuendgen, A, Levis, A, Cermak, J, Fonatsch, C, Le Beau, M M, Slovak, M L, Krieger, O, Luebbert, M, Maciejewski, J, Magalhaes, S MM, Miyazaki, Y, Pfeilstöcker, M, Sekeres, M A, Sperr, W R, Stauder, R, Tauro, S, Valent, P, Vallespi, T, van de Loosdrecht, A A, Germing, U, Haase, D, Greenberg, P L, and Cazzola, M
- Published
- 2015
- Full Text
- View/download PDF
4. Monosomal karyotype in MDS: explaining the poor prognosis?
- Author
-
Schanz, J, Tüchler, H, Solé, F, Mallo, M, Luño, E, Cervera, J, Grau, J, Hildebrandt, B, Slovak, M L, Ohyashiki, K, Steidl, C, Fonatsch, C, Pfeilstöcker, M, Nösslinger, T, Valent, P, Giagounidis, A, Aul, C, Lübbert, M, Stauder, R, Krieger, O, Le Beau, M M, Bennett, J M, Greenberg, P, Germing, U, and Haase, D
- Published
- 2013
- Full Text
- View/download PDF
5. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
- Author
-
Germing, U, Lauseker, M, Hildebrandt, B, Symeonidis, A, Cermak, J, Fenaux, P, Kelaidi, C, Pfeilstöcker, M, Nösslinger, T, Sekeres, M, Maciejewski, J, Haase, D, Schanz, J, Seymour, J, Kenealy, M, Weide, R, Lübbert, M, Platzbecker, U, Valent, P, Götze, K, Stauder, R, Blum, S, Kreuzer, K-A, Schlenk, R, Ganser, A, Hofmann, W-K, Aul, C, Krieger, O, Kündgen, A, Haas, R, Hasford, J, and Giagounidis, A
- Published
- 2012
- Full Text
- View/download PDF
6. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
- Author
-
Mallo, M, Cervera, J, Schanz, J, Such, E, García-Manero, G, Luño, E, Steidl, C, Espinet, B, Vallespí, T, Germing, U, Blum, S, Ohyashiki, K, Grau, J, Pfeilstöcker, M, Hernández, J M, Noesslinger, T, Giagounidis, A, Aul, C, Calasanz, M J, Martín, M L, Valent, P, Collado, R, Haferlach, C, Fonatsch, C, Lübbert, M, Stauder, R, Hildebrandt, B, Krieger, O, Pedro, C, Arenillas, L, Sanz, M Á, Valencia, A, Florensa, L, Sanz, G F, Haase, D, and Solé, F
- Published
- 2011
- Full Text
- View/download PDF
7. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- Author
-
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, and Papaemmanuil E
- Published
- 2021
8. Human kidney-derived cells cultured on small intestinal submucosa to generate a renal proximal tubule model: OP-045
- Author
-
Hoppensack, A, Schanz, J, Kazanecki, C, Colter, D, and Walles, H
- Published
- 2011
9. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7
- Author
-
Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, Kizilors A, Cervera J, Lea N, Ferrero D, Germing U, Hildebrandt B, Martínez ABV, Santini V, Sanz GF, Solé F, and Mufti GJ
- Subjects
DISORDERS ,ABNORMALITIES ,7Q ,MONOSOMY-7 ,KARYOTYPE ,BONE-MARROW FIBROSIS ,PROGNOSTIC SCORING SYSTEM ,LEUKEMIA ,METHYLTRANSFERASE GENE EZH2 ,ASSOCIATIONS - Abstract
Monosomy 7 [-7] and/or partial loss of chromosome 7 [del(7q)] are associated with poor and intermediate prognosis, respectively, in myelodysplastic syndromes (MDS), but somatic mutations may also play a key complementary role. We analyzed the impact on the outcomes of deep targeted mutational screening in 280 MDS patients with -7/del(7q) as isolated cytogenetic abnormality (86 with del(7q) and 194 with -7). Patients with del(7q) or -7 had similar demographic and disease-related characteristics. Somatic mutations were detected in 79% (93/117) of patients (82% in -7 and 73% in del(7q) group). Median number of mutations per patient was 2 (range 0-8). There was no difference in mutation frequency between the two groups. Patients harbouring =2 mutations had a worse outcome than patients with
- Published
- 2020
10. Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- Author
-
Bernard, E, Nannya, Y, Hasserjian, RP, Devlin, SM, Tuechler, H, Medina-Martinez, JS, Yoshizato, T, Shiozawa, Y, Saiki, R, Malcovati, L, Levine, MF, Arango, JE, Zhou, YY, Sole, F, Cargo, CA, Haase, D, Creignou, M, Germing, U, Zhang, YM, Gundem, G, Sarian, A, van de Loosdrecht, AA, Jadersten, M, Tobiasson, M, Kosmider, O, Follo, MY, Thol, F, Pinheiro, RF, Santini, V, Kotsianidis, I, Boultwood, J, Santos, FPS, Schanz, J, Kasahara, S, Ishikawa, T, Tsurumi, H, Takaori-Kondo, A, Kiguchi, T, Polprasert, C, Bennett, JM, Klimek, VM, Savona, MR, Belickova, M, Ganster, C, Palomo, L, SANZ, G, Ades, L, Della Porta, MG, Smith, AG, Werner, Y, Patel, M, Viale, A, Vanness, K, Neuberg, DS, Stevenson, KE, Menghrajani, K, Bolton, KL, Fenaux, P, Pellagatti, A, Platzbecker, U, Heuser, M, Valent, P, Chiba, S, Miyazaki, Y, Finelli, C, Voso, MT, Shih, LY, Fontenay, M, Jansen, JH, Cervera, J, Atsuta, Y, Gattermann, N, Ebert, BL, Bejar, R, Greenberg, PL, Cazzola, M, Hellstrom-Lindberg, E, Ogawa, S, and Papaemmanuil, E
- Abstract
Clinical sequencing across a large prospective cohort of patients with myelodysplasic syndrome uncovers distinct associations between the mono- and biallelic states ofTP53and clinical presentation Tumor protein p53 (TP53) is the most frequently mutated gene in cancer(1,2). In patients with myelodysplastic syndromes (MDS),TP53mutations are associated with high-risk disease(3,4), rapid transformation to acute myeloid leukemia (AML)(5), resistance to conventional therapies(6-8)and dismal outcomes(9). Consistent with the tumor-suppressive role ofTP53, patients harbor both mono- and biallelic mutations(10). However, the biological and clinical implications ofTP53allelic state have not been fully investigated in MDS or any other cancer type. We analyzed 3,324 patients with MDS forTP53mutations and allelic imbalances and delineated two subsets of patients with distinct phenotypes and outcomes. One-third ofTP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only.TP53multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System (IPSS-R)(11). Surprisingly, monoallelic patients did not differ fromTP53wild-type patients in outcomes and response to therapy. This study shows that consideration ofTP53allelic state is critical for diagnostic and prognostic precision in MDS as well as in future correlative studies of treatment response.
- Published
- 2020
11. Engineering of vascularised tissues: state of the art: Kl36
- Author
-
Mertsching, H, Schanz, J, Linke, K, Hansmann, J, Michaelis, J, Hampel, M, Brunner, H, and Walles, T
- Published
- 2007
12. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- Author
-
Bernard, E., Nannya, Y., Hasserjian, R.P., Devlin, S.M., Tuechler, H., Medina-Martinez, J.S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M.F., Arango, J.E., Zhou, Y, Solé, F., Cargo, C.A., Haase, D., Creignou, M., Germing, U., Zhang, Y., Gundem, G., Sarian, A., Loosdrecht, A.A. van de, Jädersten, M., Tobiasson, M., Kosmider, O., Follo, M.Y., Thol, F., Pinheiro, R.F., Santini, V., Kotsianidis, I., Boultwood, J., Santos, F.P.S., Schanz, J., Kasahara, S., Ishikawa, T., Tsurumi, H., Takaori-Kondo, A., Kiguchi, T., Polprasert, C., Bennett, J.M., Klimek, V.M., Savona, M.R., Belickova, M., Ganster, C., Palomo, L., Sanz, G., Ades, L., Porta, M.G. Della, Smith, A.G., Werner, Y., Patel, M., Viale, A., Vanness, K., Neuberg, D.S., Stevenson, K.E., Menghrajani, K., Bolton, K.L., Fenaux, P., Pellagatti, A., Platzbecker, U., Heuser, M., Valent, P., Chiba, S., Miyazaki, Y., Finelli, C., Voso, M.T., Shih, L.Y., Fontenay, M., Jansen, J.H., Cervera, J., Atsuta, Y., Gattermann, N., Ebert, B.L., Bejar, R., Greenberg, P.L., Cazzola, M., Hellström-Lindberg, E., Ogawa, S., Papaemmanuil, E., Bernard, E., Nannya, Y., Hasserjian, R.P., Devlin, S.M., Tuechler, H., Medina-Martinez, J.S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M.F., Arango, J.E., Zhou, Y, Solé, F., Cargo, C.A., Haase, D., Creignou, M., Germing, U., Zhang, Y., Gundem, G., Sarian, A., Loosdrecht, A.A. van de, Jädersten, M., Tobiasson, M., Kosmider, O., Follo, M.Y., Thol, F., Pinheiro, R.F., Santini, V., Kotsianidis, I., Boultwood, J., Santos, F.P.S., Schanz, J., Kasahara, S., Ishikawa, T., Tsurumi, H., Takaori-Kondo, A., Kiguchi, T., Polprasert, C., Bennett, J.M., Klimek, V.M., Savona, M.R., Belickova, M., Ganster, C., Palomo, L., Sanz, G., Ades, L., Porta, M.G. Della, Smith, A.G., Werner, Y., Patel, M., Viale, A., Vanness, K., Neuberg, D.S., Stevenson, K.E., Menghrajani, K., Bolton, K.L., Fenaux, P., Pellagatti, A., Platzbecker, U., Heuser, M., Valent, P., Chiba, S., Miyazaki, Y., Finelli, C., Voso, M.T., Shih, L.Y., Fontenay, M., Jansen, J.H., Cervera, J., Atsuta, Y., Gattermann, N., Ebert, B.L., Bejar, R., Greenberg, P.L., Cazzola, M., Hellström-Lindberg, E., Ogawa, S., and Papaemmanuil, E.
- Abstract
Contains fulltext : 229615.pdf (Publisher’s version ) (Closed access)
- Published
- 2020
13. Isolated der (1;7) fits well in the intermediate risk group of the cytogenetic scoring system for myelodysplastic syndromes
- Author
-
Ganster, C, Muller-Thomas, C, Haferlach, C, Strupp, C, Ogata, K, Germing, U, Hildebrandt, B, Mallo, M, Lubbert, M, Muller, C, Francesc Solé, Gotze, K, Vandenberghe, P, Gohring, G, Steinmetz, T, Kroeger, N, Platzbecker, U, Soling, U, Raynaud, S, Shirneshan, K, Schanz, J, and Haase, D
- Published
- 2019
14. TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (>= 3 anomalies) Aberrant Karyotypes
- Author
-
Ganster, C, Schaab, R, Shirneshan, K, Eder, LN, Mies, A, Germing, U, Elmaagacli, A, Francesc Solé, Palomo, L, Kaivers, J, Soling, U, Lange, F, Kroger, N, Hertenstein, B, Dohner, K, Bug, G, Hildebrandt, B, Parra, MT, Nickelsen, M, Glass, B, Platzbecker, U, Bacher, U, Braulke, F, Schanz, J, and Haase, D
- Published
- 2019
15. A new, simple prognostic system for complex aberrant myelodysplastic syndromes and secondary AML
- Author
-
Ganster, C, Schaab, R, Shirneshan, K, Dierks, S, Parra, MT, Martin, R, Francesc Solé, Germing, U, Palomo, L, Mies, A, Braulke, F, Hildebrandt, B, Kaivers, J, Platzbecker, U, Kroeger, N, Dohner, K, Glass, B, Elmaagacli, A, Nickelsen, M, Bacher, U, Schanz, J, and Haase, D
- Published
- 2019
16. PF553 CLONES WITH COMPLEX ABERRATIONS AND TP53 MUTATIONS RESPOND TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
- Author
-
Ganster, C., primary, Mazzeo, P., additional, Elmaagacli, A., additional, Dierks, S., additional, Shirneshan, K., additional, Scharnberg, P., additional, Martin, R., additional, Rittscher, K., additional, Götze, K., additional, Glass, B., additional, Braulke, F., additional, Schanz, J., additional, and Haase, D., additional
- Published
- 2019
- Full Text
- View/download PDF
17. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
- Author
-
Valent, P., Orazi, A., Savona, M.R., Patnaik, M.M., Onida, F., Loosdrecht, A.A. van de, Haase, D., Haferlach, T, Elena, C., Pleyer, L., Kern, W., Pemovska, T., Vladimer, G.I., Schanz, J., Keller, A., Lubbert, M., Lion, T., Sotlar, K., Reiter, A., Witte, T.J. de, Pfeilstocker, M., Geissler, K., Padron, E., Deininger, M., Orfao, A., Horny, H.P., Greenberg, P.L., Arber, D.A., Malcovati, L., Bennett, J.M., Valent, P., Orazi, A., Savona, M.R., Patnaik, M.M., Onida, F., Loosdrecht, A.A. van de, Haase, D., Haferlach, T, Elena, C., Pleyer, L., Kern, W., Pemovska, T., Vladimer, G.I., Schanz, J., Keller, A., Lubbert, M., Lion, T., Sotlar, K., Reiter, A., Witte, T.J. de, Pfeilstocker, M., Geissler, K., Padron, E., Deininger, M., Orfao, A., Horny, H.P., Greenberg, P.L., Arber, D.A., Malcovati, L., and Bennett, J.M.
- Abstract
Contains fulltext : 215300.pdf (publisher's version ) (Open Access), Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past two decades, our knowledge about the pathogenesis and molecular mechanisms in CMML has increased substantially. In parallel, better diagnostic criteria and therapeutic strategies have been developed. However, many questions remain regarding prognostication and optimal therapy. In addition, there is a need to define potential pre-phases of CMML and special CMML variants, and to separate these entities from each other and from conditions mimicking CMML. To address these unmet needs, an international consensus group met in a Working Conference in August 2018 and discussed open questions and issues around CMML, its variants, and pre-CMML conditions. The outcomes of this meeting are summarized herein and include diag nostic criteria and a proposed classification of pre-CMML conditions as well as refined minimal diagnostic criteria for classical CMML and special CMML variants, including oligomonocytic CMML and CMML associated with systemic mastocytosis. Moreover, we propose diagnostic standards and tools to distinguish between 'normal', pre-CMML and CMML entities. These criteria and standards should facilitate diagnostic and prognostic evaluations in daily practice and clinical studies in applied hematology.
- Published
- 2019
18. Genetic instability and TP53 alterations in MDS and sAML with complex aberrant karyotype
- Author
-
Schaab, R, Ganster, C, Shirneshan, K, Dierks, S, Martin, R, Francesc Solé, Germing, U, Palomo, L, Mies, A, Braulke, F, Hildebrandt, B, Kaivers, J, Platzbecker, U, Kroeger, N, Dohner, K, Glass, B, Nickelsen, M, Schanz, J, Bacher, U, and Haase, D
- Published
- 2017
19. Prueba ureteral positiva con índigo carmín, para verificar indemnidad de los uréteres en cirugía vaginal
- Author
-
Ricci Arriola, P., Pardo Schanz, J., and Solà Dalenz, V.
- Subjects
urogenital system ,mental disorders ,urologic and male genital diseases ,female genital diseases and pregnancy complications - Published
- 2010
20. Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)
- Author
-
Cervera, J., Sole, F., Haase, D., Luno, E., Such, E., Nomdedeu, B., Costa, D., Bernal, T., Vallespi, T., Bueno, J., Pedro, C., Mallo, M., Ardanaz, M. T., Calasanz, M. J., del Canizo, C., Hernandez-Rivas, J. M., Schanz, J., Steidl, C., Hildebrandt, B., Carbonell, F., Orero, M., Ramos, F., Marco, V., Tormo, M., Gomez, V., Andreu, R., Xicoy, B., Amigo, M. L., Munoz, J. A., Bonanad, S., Arrizabalaga, B., Senent, M. L., Germing, U., and Sanz, G. F.
- Published
- 2009
21. Bioartifizielle menschliche Gewebe mit eigener Gefäßversorgung als Implantate für die rekonstruktive Chirurgie: Implantatentwicklung und erste klinische Erfahrungen
- Author
-
Walles, T, Friedel, G, Schanz, J, Steger, V, Schandar, M, Hansmann, J, and Mertsching, H
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Einleitung: Seit 2 Jahrzehnten wird versucht, menschliche Gewebe für die Rekonstruktion und den Ersatz geschädigter Gewebe und Organe herzustellen (Tissue Engineering). Die Herstellung komplexer, für die rekonstruktive Chirurgie geeigneter Gewebe scheiterte jedoch an der fehlenden Vaskularisation[for full text, please go to the a.m. URL], 126. Kongress der Deutschen Gesellschaft für Chirurgie
- Published
- 2009
- Full Text
- View/download PDF
22. Corrección quirúrgica de la incontinencia de orina de esfuerzo, con cinta sintética sub-medio-uretral de tercera generación: TVT-Secur
- Author
-
Solà Dalenz, V., Ricci Arriola, P., and Pardo Schanz, J.
- Subjects
Cinta sub-medio-uretral ,Sub-mid-urethral Sling ,Cirugía mínimamente invasiva ,Stress urinary incontinence ,Minimal invasive surgery ,Incontinencia de orina de esfuerzo ,TVT-Secur - Abstract
Objetivo: Revisar nuestra experiencia inicial en la corrección de la incontinencia de orina de esfuerzo, con el nuevo sistema TVT-Secur. Revisar la efectividad y seguridad de esta técnica. Método: Entre enero y mayo del 2007, se realizaron 16 TVT-Secur (Women’s Health & Urology, Ethicon, Johnson & Johnson) a pacientes de la Unidad de Uroginecología y Cirugía Vaginal, del Departamento de Ginecología y Obstetricia de la Clínica Las Condes. En 6 pacientes la cinta se situó en "V" y en 10 en "U". La mediana de edad para el grupo fue de 52 años, índice de masa corporal 29, paridad 3. En todas se realizó estudio urodinámico previo como parte del estudio y selección preoperatoria. Todas debían tener al menos un año de incontinencia de orina de esfuerzo, y ninguna debía tener corrección quirúrgica previa. Resultado: La mediana de tiempo operatorio fue de 10 minutos, con un rango entre 8 y 15 minutos. No se presentaron complicaciones durante el acto operatorio, ni en el postoperatorio inmediato, temprano y tardío. La EVA registrada a las 12 horas fue de 1 a 2. Se obtuvo corrección de la incontinencia de orina de esfuerzo en todas las pacientes. El tiempo de seguimiento fue entre 1 y 4 meses, con una mediana de 2 meses. Todas expresaron estar conformes con los resultados de la cirugía y la recomendarían a otras pacientes en igual situación. Conclusiones: Según nuestra experiencia inicial, el nuevo sistema TVT-Secur, aparece como eficaz y seguro, en la quirúrgica de la incontinencia de orina de esfuerzo. Sin embargo, sólo el seguimiento a largo plazo, y la incorporación de nuevos pacientes al estudio, permitirá determinar el mantenimiento de estos buenos resultados en el tiempo. Objective: To review our initial experience with the new system TVT-Secur for the stress urinary incontinence. To evaluate the feasibility, efficacy and main advantages of the surgical correction with the new device. Method: Between january and may of 2007, 16 TVT-Secur (Women’s Health & Urology, Ethicon, Johnson & Johnson) were made in patients of the Urogynecology Unit, of Clínica Las Condes. Six TVT-Secur were applied in "V" and 10 in "U". The median age was 52 years old, BMI 29, parity of 3. All patients were studied with urodynamic before surgery. All must have the urinary incontinence by more of one year and no must have previous surgical correction. Results: The media surgical time was 10 minutes (8-15 minutes). Complications were not registered during intraoperative and immediate, early or delayed postoperative time. The visual analogue scale of pain was 1 to 2 at 12 hours. All patients were cured. The follow-up was between 1 and 4 months, 2 month media. All patients expressed satisfaction with the surgical results and they would recommend it to other patients in the same conditions. Conclusion: According to our initial experience, the new system TVT-Secur is feasible, safe and effective in the surgical correction of the SUI. However, only the long follow-up and the incorporation of new patients to the study, will allow to determine the permanence of these good results in the time.
- Published
- 2008
23. Estudio urodinámico en la evaluación de la incontinencia urinaria femenina, con el nuevo sistema MoniTorrMR (urodinamia monocanal con medición de presión de retro-resistencia uretral): Experiencia con 100 pacientes
- Author
-
Solà Dalenz, V., Ricci Arriola, P., and Pardo Schanz, J.
- Subjects
Incontinencia de Orina ,Urinary Incontinence ,Stress urinary incontinence ,Urodinamia ,Urodinamia Multicanal ,Incontinencia de orina de esfuerzo ,Urodinamyc ,Urodinamia Monocanal ,Multichannel Urodynamic ,URP - Abstract
Objetivos: Correlacionar el diagnóstico clínico de la incontinencia urinaria con los resultados de la cistometría (LPP) y URP, obtenidas por medio de urodinamia monocanal. Evaluar la tolerancia de los pacientes a este examen. Paciente y método: Entre agosto y diciembre del 2006, se realizaron 100 urodinamias monocanal con medición de URP, en las pacientes que consultaron por diagnóstico clínico de incontinencia de orina, en la Unidad de Uroginecología y Cirugía Vaginal, de Clínica Las Condes. Se correlacionó el diagnóstico clínico con los resultados de la urodinamia. Se aplicó una escala de tolerancia subjetiva del examen, donde 0 es la mayor tolerancia y 10 la menor. Resultados: De las 66 pacientes con clínica de incontinencia de orina de esfuerzo: 10 fueron tipo 0, 2 tipo I, 23 tipo II, 1 tipo III, 17 tipo II+III, 1 detrusor hiperactivo, 5 tipo 0+detrusor hiperactivo, 3 tipo II+detrusor hiperactivo, 4 II+III+detrusor hiperactivo. De las 15 pacientes con IOM: 6 urodinamias fueron tipo 0, 2 tipo II, 2 tipo II+III, 3 detrusor hiperactivo, 1 tipo II+detrusor hiperactivo y 1 tipo III+detrusor hiperactivo. De las 16 pacientes con urgeincontinencia: 2 normal, 4 II+III, 7 detrusor hiperactivo, 1 II+detrusor hiperactivo y 2 II+III+detrusor hiperactivo. En 3 pacientes se solicitó una urodinamia como parte del estudio pre-operatorio, por corresponder respectivamente a dos casos de prolapso de cúpula y un cistocele, todos grado IV (POP-Q), con una gran potencialidad de incontinencia de orina después de la corrección. Presentaron respectivamente una incontinencia de esfuerzo tipo III+detrusor hiperactivo, una tipo II+III y una urodinamia normal. Todas las pacientes identificaron una tolerancia que clasificaron como 2 o 3 (escala de 0 a 10, donde 0 corresponde al grado mayor tolerancia y 10 al grado de menor tolerancia). Conclusiones: La urodinamia monocanal más la medición de la URP es un examen complementario de gran utilidad en la objetivación y clasificación del diagnóstico de la incontinencia urinaria, sospechada por la clínica. Permite al médico planificar la solución adecuada para cada caso y tiene un alto grado de tolerancia en las pacientes. Objective: To compare the clinical diagnosis of the urinary incontinence with the results of LPP and URP obtained by non-multichannel urodynamic. To evaluate the tolerance of the patients to this examination. Pathient and Method: Between August and December 2006, 100 urodynamics were made in patients with clinical diagnosis of urinary incontinence, in the Urogynecology Unit of Clínica Las Condes. The clinical diagnosis was compared with the urodynamic results. A subjective tolerance scale was applied (0 was greater tolerance and 10 was maximum discomfort). Results: In 66 patients with clinical diagnosis of IUS, the urodynamic registered 10 Type 0, 2 (I), 23 (II), 1 (III), 17 (II+III),1 hyperactive detrusor, 5 (0+ hyperactive detrusor), 3 (II+hyperactive detrusor) and 4 (II+III+hyperactive detrusor). In 15 with Mixed urinary incontinence, the urodynamic showed 6 (Type 0), 2 (II), 2 (II+III), 3 hyperactive detrusor, 1 (II+hyperactive detrusor) and 1 (III+hyperactive detrusor). In 16 patients with urgency incontinence, urodynamic showed 2 normal, 4 (II+III), 7 hyperactive detrusor, 1 (II+hyperactive detrusor) and 2 (II+III+hyperactive detrusor). In 3 patients (two vaginal cuff prolapse and one cistocele, degree IV POP-Q) the urodynamic was indicated in the pre-surgery study considering a great potentially incontinence after correction. Respectively, the patients presented: IUS type III+hyperactive detrusor, IUS type II+III and one normal. All patients expressed 2 and 3 degree tolerance (subjective scale: 1 major tolerance and 10 a minor tolerance). Conclusions: The MoniTorrMR urodynamic is a complementary examination very useful in the study of the urinary incontinence. It allows planning the solution adapted for each case and has a high degree of tolerance in the patients.
- Published
- 2008
24. PROGNOSTIC IMPACT OF ADDITIONAL CHROMOSOMAL ABERRATIONS TO 5Q-IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROMES
- Author
-
Mallo, M., Cervera, J., Schanz, J., Espinet, B., Such, E., Luno, E., Steidl, C., Martin, M. L., Germing, U., Granada, I., Pfeilstoecker, M., Hernandez, J. M., Noesslinger, T., Calasanz, M. J., Valent, P., Collado, R., Fonatsch, C., Bureo, E., Luebbert, M., Rios, R., Stauder, R., Arranz, E., Hildebrandt, B., Cigudosa, J. C., Pedro, C., Salido, M., Arenillas, L., Sanz, G. F., Sanz, M. A., Valencia, A., and Florensa, L.
- Published
- 2008
25. Cinta trans-obturadora (TOT) en la corrección de la incontinencia de orina de esfuerzo: Experiencia de tres años con 200 pacientes
- Author
-
Pardo Schanz, J., Ricci Arriola, P., Tacla Fernández, X., and Betancourt Ortiz, E.
- Subjects
Cinta Trans-obturadora ,TOT ,Stress urinary incontinente ,Cinta suburetral ,Incontinencia de orina de esfuerzo ,Urinary incontinence ,Midurethral swing ,Trans obturator tape ,Incontinencia de orina - Abstract
Objetivo: Evaluar la seguridad y eficacia del TOT en el tratamiento de la incontinencia de orina de esfuerzo femenina, de acuerdo a nuestra experiencia. Paciente y Método: Estudio prospectivo de 200 pacientes a los que se realizó TOT en la Unidad de Ginecología del Departamento de Obstetricia y Ginecología del Hospital Barros Luco-Trudeau, entre enero del 2003 y octubre del 2006. Se utilizó malla de polipropileno, macroporo, monofilamento (Prolene). Mediana de edad 52 años, paridad 3. Resultados: El tiempo operatorio del TOT fue de 15 minutos (mediana). De las 200 pacientes, al mes se constató curación de la incontinencia de esfuerzo en 184 (92%), 6 (3%) casos mejoría, 10 (5%) casos falla de la cirugía. Se presentaron 3 complicaciones intraoperatorias, correspondiendo a lesión de vejiga. Una con la tijera durante la disección del espacio vesico-vaginal hacia el agujero obturador y dos con la aguja. Durante el postperatorio inmediato se evidenció un caso de obstrucción parcial de uretra por inflamación, dos casos de infección urinaria y tres casos con dolor de extremidades inferiores. Durante el postoperatorio tardío en una paciente con cura, como consecuencia de una caída violenta, se reinicia la incontinencia. Conclusión: De acuerdo a nuestra experiencia con 200 casos, el TOT se presenta como una técnica segura y eficaz en el tratamiento quirúrgico de la incontinencia de orina de esfuerzo. Objective: To evaluate the security and effectiveness of the TOT in the female incontinence surgical treatment according to our experience. Patient and Method: Prospective study of 200 patients underwent TOT at Gynecology Unit of the Obstetrics and Gynecology Department in Barros Luco-Trudeau Hospital between January 2003 and October 2006. Polypropilene, macropore, mofilament mesh (Prolene) was used. The mean age was 52 years old, parity 3. Results: The mean surgical time of TOT was 15 minutes. In 184 (92%) patients obtained cure, 6 (3%) improvement and 10 (5%) fails. Three cases of bladder injury occurred (one perforation with the scissor and two with TOT needle during the learning phase). During the immediately postoperative time: one case of partial urethral obstruction, two cases of urinary infection and three with pain of the legs. During the delayed postoperative time a case of fail was observed after trauma. Conclusion: According to our experience with 200 cases, the TOT appears as a safe and effective technique in the surgical treatment of the stress urinary incontinence.
- Published
- 2007
26. Sistema Prolift en la corrección del prolapso genital femenino
- Author
-
Solà Dalenz, V., Pardo Schanz, J., Ricci Arriola, P., and Guiloff Fische, E.
- Subjects
Prolift ,Rectocele ,Genital Prolapse ,Gynemesh PS ,Cistocele ,Prolapso ,Cystocele - Abstract
Objetivo: Revisar la seguridad y eficacia de la corrección de prolapso genital femenino con el nuevo sistema Prolift. Paciente y Método: Estudio prospectivo de 41 pacientes ingresados para corrección quirúrgica de prolapso anterior y/o posterior genital, entre julio del 2006 y mayo del 2007, en la Unidad de Uroginecología y Cirugía Vaginal de Clínica Las Condes. El periodo de observación fue hasta julio del 2007. Resultados: Se corrigieron 29 cistoceles: 13 grado II, 14 grado III y 3 grado IV. Treinta rectoceles: 12 grado II, 16 grado III y 3 grado IV. Cinco casos de prolapso de cúpula (malla total, anterior y posterior): 1 grado II y 4 grado IV. El tiempo quirúrgico para Prolift anterior fue de 40 minutos (30 a 50 minutos). Para Prolift posterior 30 minutos (20 a 40 minutos). Para Prolift Total en cúpula 60 minutos (40 a 70 minutos). No se registraron complicaciones durante el intraoperatorio. En el postoperatorio inmediato se registró un caso de hematoma perirectal en un paciente con malla posterior para corrección de rectocele. Se trató sólo con anti-inflamatorios. Durante el postoperatorio tardío se registró un caso de erosión vaginal y exposición de 0, 5 cms de malla en un caso de prolapso de cúpula, corregido con malla total. Se registraron 2 recidivas asintomáticas en prolapso de cúpula. Una de grado IV a grado III y otra de grado IV, que se presentó como cistocele grado II. La escala visual análoga del dolor en pacientes con Prolift anterior solamente, a las 12 horas 3-4, 24 horas 2 y 48 horas 1. En Prolift posterior solamente, a las 12 horas 4-6, 24 horas 3-4 y 48 horas 1-2. En los casos con Prolift anterior y posterior, y en los casos de prolapso de cúpula, los valores no variaron respecto a los de Prolift posterior. Respecto al grado de satisfacción preguntado durante el control a los 30 días, todas respondieron estar muy satisfechas. La media de seguimiento de las 41 pacientes fue de 7 meses (rango de 2 a 12 meses). Conclusión: Según nuestra experiencia la corrección del prolapso genital femenino con el Sistema Prolift es seguro y eficaz, sin embargo debemos tener presente que se requiere un seguimiento a largo plazo para registrar el mantenimiento de los buenos resultados. Objective: To review the security and effectiveness of female genital prolapse using the new Prolift system. Patient and Method: Prospective study of 41 patients that have been submitted to correction of cystocele and/or rectocele or vaginal cuff, between July of 2006 and May of 2007 in the Urogynecology and Vaginal Surgery Unit of Clínica Las Condes. The period of observation was completed at July of 2007. Result: Anterior Prolift mesh was used in 29 cystocele: 13 degree II, 14 degree III and 3 degree IV. Thirty rectocele: 12 degree II, 16 degree III and 3 degree IV. Five cases of vaginal cuff prolapse (total mesh): 1 degree II and 4 degree IV. The media time of surgery was 40 minutes for anterior Prolift (30 to 50 minutes); 30 minutes (20 to 40 minutes) for posterior Prolift and 60 minutes for Total Prolift. They did not present intraoperative complications. During the immediate postoperative time a case of peri-rectal hematoma was observed in a patient with posterior mesh for the rectocele correction. It was treated with oral anti-inflammatory. During the delayed postoperative time a case of vaginal erosion and mesh exposition (0.5 centimeters) was observed in a case of vaginal cuff prolapse treated with a Total Prolift. Two asymptomatic recidivate vaginal cuff prolapse were registered; degree IV to III and a case degree IV that was recidivate to cystocele degree II. The visual analogue scale of pain in Anterior Prolift was 3-4 at 12 hours, 2 at 24 hours and 1 at 48 hours. In Posterior Prolift was 4-6 at 12 hours, 3-4 at 24 hours and 1-2 at 48 hours. In cases with Anterior and Posterior Prolift and in Total Prolift the results were the same of Posterior Prolift. All patients indicated satisfaction in the follow-up at 30 days. The media follow up in the 41 patients was 7 months (range of 2 to 12 months). Conclusion: According to our experience the correction of the female genital prolapse with Prolift system is safe and effective; nevertheless a long follow-up is required to observe the good results in the time.
- Published
- 2007
27. Malla de polipropileno monofilamento libre de tensión en la reparación concomitante de cistocele y rectocele
- Author
-
Solà Dalenz, V., Pardo Schanz, J., Ricci Arriola, P., and Guiloff Fische, E.
- Subjects
Libre de tensión ,Rectocele ,Reparación de prolapso de órganos pélvicos ,Tension free ,Polypropylene mesh ,Cistocele ,Malla de polipropileno ,Pelvic organ prolapse (POP) repair ,Cystocele - Abstract
Objetivo: Presentamos nuestra experiencia en la corrección de cistocele y rectocele concomitante, con malla de polipropileno monofilamento (Gynemesh PS), con técnica libre de tensión transvaginal. Método: Entre noviembre 2004 y enero 2005 se realizó corrección 7 pacientes, de la Unidad de Uroginecología y Cirugía Vaginal del Departamento de Ginecología y Obstetricia, de la Clínica Las Condes. Mediana de edad 54 años, peso 64 kg. En cuatro pacientes además se asoció una tercera malla para corrección de incontinencia de orina de esfuerzo, con técnica de TVT-O. Resultado: No se presentaron complicaciones intraoperatorias, ni en el postoperatorio inmediato ni tardío. No se observó hematoma, infección, ni exposición de la malla. Se obtuvo curación del cistocele y del rectocele en el 100% de las pacientes. No se han presentado a la fecha actual, completando 3 meses de observación 4 casos, 2 meses 2 casos, y 1 mes un caso. Discusión: La utilización de mallas protésicas, de polipropileno monofilamento con macroporo en la corrección concomitante del cistocele y del rectocele, por vía transvaginal, con técnica libre de tensión, parece ser un procedimiento seguro y eficaz. Objective: We presented our experience in the concomitant correction of cystocele and rectocele with polypropylene monofilament mesh (Gynemesh PS), with transvaginal free tension technique. Method: During 2004 correction was made in 7 patients, Urogynecologic and Vaginal Surgery Unit of Gynecology and Obstetrics Department, Las Condes Clinic. Medium age 54 years old, weight 64 kgs. In four patients we used a third mesh for correction of urinary incontinence by TVT-O. Results: They don’t present intraoperative complications, neither in immediate or delayed postoperative time. We not observed hematoma, infection, erosion or exposition mesh. Cure of cystocele and rectocele was in the 100% of patients. Complications have not appeared, 4 cases completed three months of observation, 2 cases two months and 1 case one month. Discussion: The use of protesic polypropylene multifilament macropore mesh in the concomitant correction of cistocele and rectocele, by transvaginal route with tension free technique seems to be a safe and effective surgery procedure.
- Published
- 2005
28. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group
- Author
-
Braulke, F., primary, Platzbecker, U., additional, Muller-Thomas, C., additional, Gotze, K., additional, Germing, U., additional, Brummendorf, T. H., additional, Nolte, F., additional, Hofmann, W.-K., additional, Giagounidis, A. A. N., additional, Lubbert, M., additional, Greenberg, P. L., additional, Bennett, J. M., additional, Sole, F., additional, Mallo, M., additional, Slovak, M. L., additional, Ohyashiki, K., additional, Le Beau, M. M., additional, Tuchler, H., additional, Pfeilstocker, M., additional, Nosslinger, T., additional, Hildebrandt, B., additional, Shirneshan, K., additional, Aul, C., additional, Stauder, R., additional, Sperr, W. R., additional, Valent, P., additional, Fonatsch, C., additional, Trumper, L., additional, Haase, D., additional, and Schanz, J., additional
- Published
- 2014
- Full Text
- View/download PDF
29. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
- Author
-
Muller-Thomas, C., primary, Rudelius, M., additional, Rondak, I.-C., additional, Haferlach, T., additional, Schanz, J., additional, Huberle, C., additional, Schmidt, B., additional, Blaser, R., additional, Kremer, M., additional, Peschel, C., additional, Germing, U., additional, Platzbecker, U., additional, and Gotze, K., additional
- Published
- 2014
- Full Text
- View/download PDF
30. A deaf mother and son with diabetes and renal failure
- Author
-
Schanz, J., primary, Rudofsky, G., additional, Runz, H., additional, and Rath, T., additional
- Published
- 2012
- Full Text
- View/download PDF
31. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
- Author
-
Mallo, M, primary, Cervera, J, additional, Schanz, J, additional, Such, E, additional, García-Manero, G, additional, Luño, E, additional, Steidl, C, additional, Espinet, B, additional, Vallespí, T, additional, Germing, U, additional, Blum, S, additional, Ohyashiki, K, additional, Grau, J, additional, Pfeilstöcker, M, additional, Hernández, J M, additional, Noesslinger, T, additional, Giagounidis, A, additional, Aul, C, additional, Calasanz, M J, additional, Martín, M L, additional, Valent, P, additional, Collado, R, additional, Haferlach, C, additional, Fonatsch, C, additional, Lübbert, M, additional, Stauder, R, additional, Hildebrandt, B, additional, Krieger, O, additional, Pedro, C, additional, Arenillas, L, additional, Sanz, M Á, additional, Valencia, A, additional, Florensa, L, additional, Sanz, G F, additional, Haase, D, additional, and Solé, F, additional
- Published
- 2010
- Full Text
- View/download PDF
32. GEMINI FUEL CELL POWER SOURCE - FIRST SPACECRAFT APPLICATION
- Author
-
Bullock, E. K and Schanz, J. L
- Subjects
Chemistry - Abstract
Design and development of the ion-exchange membrane fuel cell intended to furnish electric power and drinking water to the gemini spacecraft
- Published
- 1962
33. Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.
- Author
-
Haase, D., primary, Steidl, C., primary, Schanz, J., primary, Schabla, R., primary, Pfeilstöcker, M., primary, Nösslinger, T., primary, Hildebrandt, B., primary, Kuendgen, A., primary, Lübbert, M., primary, Kunzmann, B., primary, Giagounidis, A., primary, Aul, C., primary, Trümper, L., primary, Krieger, O., primary, Fonatsch, C., primary, Valent, P., primary, Stauder, R., primary, and Germing, U., primary
- Published
- 2005
- Full Text
- View/download PDF
34. Experimental generation of a tissue-engineered functional and vascularized trachea
- Author
-
WALLES, T, primary, GIERE, B, additional, HOFMANN, M, additional, SCHANZ, J, additional, HOFMANN, F, additional, MERTSCHING, H, additional, and MACCHIARINI, P, additional
- Published
- 2004
- Full Text
- View/download PDF
35. Objectivity in the Courts
- Author
-
Schanz, J. J., primary
- Published
- 1969
- Full Text
- View/download PDF
36. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- Author
-
Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan S. Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max F. Levine, Juan E. Arango, Yangyu Zhou, Francesc Solé, Catherine A. Cargo, Detlef Haase, Maria Creignou, Ulrich Germing, Yanming Zhang, Gunes Gundem, Araxe Sarian, Arjan A. van de Loosdrecht, Martin Jädersten, Magnus Tobiasson, Olivier Kosmider, Matilde Y. Follo, Felicitas Thol, Ronald F. Pinheiro, Valeria Santini, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio P. S. Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori-Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Belickova, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Ades, Matteo Giovanni Della Porta, Harold K. Elias, Alexandra G. Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna S. Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil, Bernard E., Nannya Y., Hasserjian R.P., Devlin S.M., Tuechler H., Medina-Martinez J.S., Yoshizato T., Shiozawa Y., Saiki R., Malcovati L., Levine M.F., Arango J.E., Zhou Y., Sole F., Cargo C.A., Haase D., Creignou M., Germing U., Zhang Y., Gundem G., Sarian A., van de Loosdrecht A.A., Jadersten M., Tobiasson M., Kosmider O., Follo M.Y., Thol F., Pinheiro R.F., Santini V., Kotsianidis I., Boultwood J., Santos F.P.S., Schanz J., Kasahara S., Ishikawa T., Tsurumi H., Takaori-Kondo A., Kiguchi T., Polprasert C., Bennett J.M., Klimek V.M., Savona M.R., Belickova M., Ganster C., Palomo L., Sanz G., Ades L., Della Porta M.G., Smith A.G., Werner Y., Patel M., Viale A., Vanness K., Neuberg D.S., Stevenson K.E., Menghrajani K., Bolton K.L., Fenaux P., Pellagatti A., Platzbecker U., Heuser M., Valent P., Chiba S., Miyazaki Y., Finelli C., Voso M.T., Shih L.-Y., Fontenay M., Jansen J.H., Cervera J., Atsuta Y., Gattermann N., Ebert B.L., Bejar R., Greenberg P.L., Cazzola M., Hellstrom-Lindberg E., Ogawa S., Papaemmanuil E., Hematology, and CCA - Cancer biology and immunology
- Subjects
Male ,0301 basic medicine ,Oncology ,endocrine system diseases ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,DNA Mutational Analysis ,Loss of Heterozygosity ,Medical and Health Sciences ,Cohort Studies ,Loss of heterozygosity ,0302 clinical medicine ,Gene Frequency ,2.1 Biological and endogenous factors ,Medicine ,Aetiology ,Cancer ,DNA Copy Number Variation ,Allele ,0303 health sciences ,Myeloid leukemia ,Hematology ,General Medicine ,Prognosis ,3. Good health ,Phenotype ,Treatment Outcome ,International Prognostic Scoring System ,030220 oncology & carcinogenesis ,Cohort ,Female ,Survival Analysi ,Human ,medicine.medical_specialty ,DNA Copy Number Variations ,Prognosi ,Immunology ,Myelodysplastic Syndrome ,Locus (genetics) ,Article ,Genomic Instability ,General Biochemistry, Genetics and Molecular Biology ,DNA Mutational Analysi ,03 medical and health sciences ,Rare Diseases ,Clinical Research ,Internal medicine ,Complex Karyotype ,Genetics ,Humans ,Clinical significance ,Allele frequency ,neoplasms ,Gene ,Alleles ,Survival analysis ,030304 developmental biology ,business.industry ,Myelodysplastic syndromes ,Stem Cell Research ,Settore MED/15 ,medicine.disease ,Survival Analysis ,030104 developmental biology ,Myelodysplastic Syndromes ,Mutation ,Cohort Studie ,Tumor Suppressor Protein p53 ,TP53 mutations, myelodyspastic syndromes, prognosis, lenalidomide ,business - Abstract
Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6–8 and dismal outcomes9. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations10. However, the biological and clinical implications of TP53 allelic state have not been fully investigated in MDS or any other cancer type. We analyzed 3,324 patients with MDS for TP53 mutations and allelic imbalances and delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only. TP53 multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System (IPSS-R)11. Surprisingly, monoallelic patients did not differ from TP53 wild-type patients in outcomes and response to therapy. This study shows that consideration of TP53 allelic state is critical for diagnostic and prognostic precision in MDS as well as in future correlative studies of treatment response. Clinical sequencing across a large prospective cohort of patients with myelodysplasic syndrome uncovers distinct associations between the mono- and biallelic states of TP53 and clinical presentation
- Published
- 2020
- Full Text
- View/download PDF
37. Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS.
- Author
-
Mazzeo P, Ganster C, Wiedenhöft J, Shirneshan K, Rittscher K, Brzuszkiewicz EB, Steinemann D, Schieck M, Müller-Thomas C, Treiber H, Braulke F, Germing U, Sockel K, Balaian E, Schanz J, Platzbecker U, Götze KS, and Haase D
- Abstract
The acquisition of subsequent genetic lesions (clonal evolution, CE) and/or the expansion of existing clones (CEXP) contributes to clonal dynamics (CD) in myelodysplastic syndromes (MDS). Although CD plays an important role in high-risk patients in disease progression and transformation into acute myeloid leukemia (AML), knowledge about CD in lower-risk MDS (LR-MDS) patients is limited due to lack of robust longitudinal data considering the long clinically stable courses of the disease. In this retrospective analysis, we delineate the frequency and the prognostic impact of CD in an unselected real-world cohort of LR-MDS patients. We screened 68 patients with a median follow-up of 40.5 months and a median of 7.5 (range: 2-22) timepoints for CE and CEXP detected by chromosomal banding analysis, fluorescence in situ hybridization, sequencing, and molecular karyotyping. In 30/68 patients, 47 CE events and a CD rate of 1 event per 4 years were documented. Of note, patients with at least 1 CE event had an increased probability for subsequent treatment. Unexpectedly, CE did not correlate with inferior outcomes, which could be reasonably explained by CD detection triggering the subsequent start of a disease-modifying therapy., Competing Interests: Detlef Haase is a member of the Advisory board and received research support, as well as honoraria from Bristol Myers Squibb and Celgene. All other authors declare no conflict of interest., (© 2024 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.)
- Published
- 2024
- Full Text
- View/download PDF
38. Tolerability and first hints for potential efficacy of motor-cognitive training under inspiratory hypoxia in health and neuropsychiatric disorders: A translational viewpoint.
- Author
-
Mennen SS, Franta M, Begemann M, Wilke JBH, Schröder R, Butt UJ, Cortés-Silva JA, Çakır U, Güra M, de Marées M, Gastaldi VD, Burtscher J, Schanz J, Bohn M, Burtscher M, Fischer A, Poustka L, Hammermann P, Stadler M, Lühder F, Singh M, Nave KA, Miskowiak KW, and Ehrenreich H
- Abstract
Hypoxia is more and more perceived as pivotal physiological driving force, allowing cells in the brain and elsewhere to acclimate to lowered oxygen (O
2 ), and abridged metabolism. The mediating transcription program is induced by inspiratory hypoxia but also by intensive motor-cognitive tasks, provoking a relative decrease in O2 in relation to the acutely augmented requirement. We termed this fundamental, demand-dependent drop in O2 availability "functional hypoxia." Major players in the hypoxia response are hypoxia-inducible factors (HIFs) and associated prolyl-hydroxylases. HIFs are transcription factors, stabilized by low O2 accessibility, and control expression of a multitude of genes. Changes in oxygen, however, can also be sensed via other pathways, among them the thiol-oxidase (2-aminoethanethiol) dioxygenase. Considering the far-reaching biological response to hypoxia, hitherto mostly observed in rodents, we initiated a translational project, combining mild to moderate inspiratory with functional hypoxia. We had identified this combination earlier to benefit motor-cognitive attainment in mice. A total of 20 subjects were included: 13 healthy individuals and 7 patients with depression and/or autism spectrum disorder. Here, we show that motor-cognitive training under inspiratory hypoxia (12% O2 ) for 3.5 h daily over 3 weeks is optimally tolerated. We present first signals of beneficial effects on general well-being, cognitive performance, physical fitness and psychopathology. Erythropoietin in serum increases under hypoxia and flow cytometry analysis of blood reveals several immune cell types to be mildly modulated by hypoxia. To obtain reliable information regarding the "add-on" value of inspiratory on top of functional hypoxia, induced by motor-cognitive training, a single-blind study-with versus without inspiratory hypoxia-is essential and outlined here., Competing Interests: Conflict of Interest Statement The authors declare no conflict of interest.- Published
- 2024
- Full Text
- View/download PDF
39. Clonal hematopoiesis with TET2 mutations spawning synchronous primary central nervous system lymphoma and myelodysplastic syndrome.
- Author
-
Treiber H, Ganster C, Schanz J, Shimono J, Zechel S, Pohanyar N, Riedel C, Stadelmann C, Haase D, Trümper L, Chapuy B, and Wulf GG
- Subjects
- Humans, Clonal Hematopoiesis, Mutation, Central Nervous System pathology, Hematopoiesis genetics, DNA-Binding Proteins genetics, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes pathology, Lymphoma, Dioxygenases genetics
- Published
- 2023
- Full Text
- View/download PDF
40. AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study.
- Author
-
Arras P, Yoo HB, Pekar L, Clarke T, Friedrich L, Schröter C, Schanz J, Tonillo J, Siegmund V, Doerner A, Krah S, Guarnera E, Zielonka S, and Evers A
- Abstract
Introduction: In this study, we demonstrate the feasibility of yeast surface display (YSD) and nextgeneration sequencing (NGS) in combination with artificial intelligence and machine learning methods (AI/ML) for the identification of de novo humanized single domain antibodies (sdAbs) with favorable early developability profiles. Methods: The display library was derived from a novel approach, in which VHH-based CDR3 regions obtained from a llama (Lama glama), immunized against NKp46, were grafted onto a humanized VHH backbone library that was diversified in CDR1 and CDR2. Following NGS analysis of sequence pools from two rounds of fluorescence-activated cell sorting we focused on four sequence clusters based on NGS frequency and enrichment analysis as well as in silico developability assessment. For each cluster, long short-term memory (LSTM) based deep generative models were trained and used for the in silico sampling of new sequences. Sequences were subjected to sequence- and structure-based in silico developability assessment to select a set of less than 10 sequences per cluster for production. Results: As demonstrated by binding kinetics and early developability assessment, this procedure represents a general strategy for the rapid and efficient design of potent and automatically humanized sdAb hits from screening selections with favorable early developability profiles., Competing Interests: PA, HY, LP, LF, VS, AD, SK, EG, SZ, AE were employed by Merck Healthcare KGaA. CS, JS, JT were employed by Merck KGaA. TC was employed by EMD Serono., (Copyright © 2023 Arras, Yoo, Pekar, Clarke, Friedrich, Schröter, Schanz, Tonillo, Siegmund, Doerner, Krah, Guarnera, Zielonka and Evers.)
- Published
- 2023
- Full Text
- View/download PDF
41. Joining of Aluminum and CFRP via Laser Powder Bed Fusion: Influence of Experimental Set-Up and Laser Processing on Microstructure and Mechanical Properties.
- Author
-
Nester S, Meinhard D, Schanz J, Rettenberger M, Taha I, Riegel H, and Knoblauch V
- Abstract
Additive-manufacturing-based joining methods enable tailored or even functionalized joints and allow for hybridization at small scales. The current study explored an innovative joining method for aluminum cast alloys (AlSi12) with thermoset carbon-fiber-reinforced polymers (CFRPs) via laser powder bed fusion (LPBF). The direct build-up of AlSi12 on a CFRP substrate proved to be challenging due to the dissimilar thermal properties of the considered materials, which led to substrate damage and low joint adhesion. These effects could be overcome by introducing an AlSi12 foil as an interlayer between the two joining partners, acting as a thermal barrier and further improving the AlSi12 melt wettability of the substrate. Within LPBF, the energy input in the form of volumetric laser energy density influenced both the porosity of the fused layers and the formation of thermally induced stresses due to the high cooling rates and different thermal expansion properties of the materials. While the AlSi12 volume density increased with a higher laser energy input, simultaneously increasing thermal stresses caused the debonding and deformation of the AlSi12 foil. However, within a narrow processing window of laser parameters, the samples achieved remarkably high shear strengths of τ > 20 MPa, comparable to those of conventional joining methods.
- Published
- 2023
- Full Text
- View/download PDF
42. Retraction notice to: Vascularised human tissue models: A new approach for the refinement of biomedical research Journal of Biotechnology 148 (2010) 56-63.
- Author
-
Schanz J, Pusch J, Hansmann J, and Walles H
- Published
- 2022
- Full Text
- View/download PDF
43. Additive Manufacturing of CrFeNiTi Multi-Principal Element Alloys.
- Author
-
Reiberg M, Hitzler L, Apfelbacher L, Schanz J, Kolb D, Riegel H, and Werner E
- Abstract
High entropy alloys (HEAs) and their closely related variants, called multi-principal element alloys (MPEAs), are the topic of a rather new area of research, and so far, the gathered knowledge is incomplete. This is especially true when it comes to material libraries, as the fabrication of HEA and MPEA samples with a wide variation in chemical compositions is challenging in itself. Additive manufacturing technologies are, to date, seen as possibly the best option to quickly fabricate HEA and MPEA samples, offering both the melting metallurgical and solid-state sintering approach. Within this study, CrFeNiTi MPEA samples were fabricated via laser powder-bed fusion (PBF-LB) and solid-state sintering of mechanically alloyed powder feedstock. The main emphasis is on the PBF-LB process, while solid-state sintering serves as benchmark. Within a volumetric energy density (VED) window of 50 J/mm
3 to 83 J/mm3 , dense samples with large defect-free sections and an average micro-hardness of 965 HV0.1 were fabricated. Clear correlations between the local chemical alloy composition and the related micro-hardness were recorded, with the main factor being the evaporation of titanium at higher VED settings through a reduction in the C14_Laves phase fraction.- Published
- 2022
- Full Text
- View/download PDF
44. Comparison and Harmonization of Different Semi-Automated and Automated qRT-PCR Assays in the Assessment of SARS-CoV-2.
- Author
-
Dierks S, Thiele K, Bohne W, Lugert R, Weig M, Groß U, von Ahsen N, Schanz J, Fischer A, and Schnelle M
- Subjects
- Sheep, Animals, Humans, SARS-CoV-2 genetics, COVID-19 Testing, Reverse Transcriptase Polymerase Chain Reaction, Sensitivity and Specificity, Scrapie, COVID-19 diagnosis
- Abstract
In SARS-CoV-2 diagnostics, cycle threshold (Ct) values from qRT-PCRs semi-quantitatively estimate a patient's viral load. However, relevant analytical differences between qRT-PCR assays are often neglected. This study was designed (i) to identify such differences between five commonly used assays and (ii) to demonstrate a straightforward strategy to harmonize them. QRT-PCRs for SARS-CoV-2 were carried out in 85 oropharyngeal swab samples using three fully automated (Alinity m, cobas
® 6800 and GeneXpert) and two semi-automated (genesig® and RIDA® GENE) assays. Qualitative results (positive/negative) showed excellent comparability between the fully automated assays, but not between the Alinity m and semi-automated methods. Ct values significantly varied between all the methods, with the median values ranging from 22.76 (Alinity m) to 30.89 (RIDA® GENE) and 31.50 (genesig® ), indicating the lowest sensitivity for semi-automated methods. Passing-Bablok analysis further revealed systemic biases. Assay-specific viral load concentration calculations-based on generated individual standard curves-resulted in much better comparability between the assays. Applying these calculations, significant differences were no longer detectable. This study highlights relevant analytical differences between SARS-CoV-2 qRT-PCR assays, leading to divergent decisions about the mandatory isolation of infected individuals. Secondly, we propose a strategy to harmonize qRT-PCR assays to achieve better comparability. Our findings are of particular interest for laboratories utilizing different assays.- Published
- 2022
- Full Text
- View/download PDF
45. Case Report: Interferon- γ Rescues Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) Function in a COVID-19 Patient With ARDS and Superinfection With Multiple MDR 4MRGN Bacterial Strains.
- Author
-
Grimm C, Dickel S, Grundmann J, Payen D, Schanz J, Zautner AE, Tampe B, Moerer O, and Winkler MS
- Subjects
- Adult, Humans, Receptors, Interferon immunology, Interferon gamma Receptor, Bacteria immunology, COVID-19 immunology, Drug Resistance, Multiple immunology, HLA Antigens immunology, Interferon-gamma immunology, Monocytes immunology, Respiratory Distress Syndrome immunology
- Abstract
Background: CD14+ monocytes present antigens to adaptive immune cells via monocytic human leukocyte antigen receptor (mHLA-DR), which is described as an immunological synapse. Reduced levels of mHLA-DR can display an acquired immune defect, which is often found in sepsis and predisposes for secondary infections and fatal outcomes. Monocytic HLA-DR expression is reliably induced by interferon- γ (IFNγ) therapy., Case Report: We report a case of multidrug-resistant superinfected COVID-19 acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO) support. The resistance profiles of the detected Klebsiella pneumoniae , Pseudomonas aeruginosa, Acinetobacter baumannii and Citrobacter freundii isolates were equipped with resistance to all four antibiotic classes including carbapenems (4MRGN) and Cefiderocol in the case of K. pneumoniae . A causal therapeutic antibiotic strategy was not available. Therefore, we measured the immune status of the patient aiming to identify a potential acquired immune deficiency. Monocyte HLA-DR expression identified by FACS analysis revealed an expression level of 34% positive monocytes and suggested severe immunosuppression. We indicated IFNγ therapy, which resulted in a rapid increase in mHLA-DR expression (96%), rapid resolution of invasive bloodstream infection, and discharge from the hospital on day 70., Discussion: Superinfection is a dangerous complication of COVID-19 pneumonia, and sepsis-induced immunosuppression is a risk factor for it. Immunosuppression is expressed by a disturbed antigen presentation of monocytes to cells of the adaptive immune system. The case presented here is remarkable as no validated antibiotic regimen existed against the detected bacterial pathogens causing bloodstream infection and severe pneumonia in a patient suffering from COVID-19 ARDS. Possible restoration of the patient's own immunity by IFNγ was a plausible option to boost the patient's immune system, eliminate the identified 4MRGNs, and allow for lung recovery. This led to the conclusion that immune status monitoring is useful in complicated COVID-19-ARDS and that concomitant IFNγ therapy may support antibiotic strategies., Conclusion: After a compromised immune system has been detected by suppressed mHLA-DR levels, the immune system can be safely reactivated by IFNγ., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Grimm, Dickel, Grundmann, Payen, Schanz, Zautner, Tampe, Moerer and Winkler.)
- Published
- 2021
- Full Text
- View/download PDF
46. Laser Polishing of Additive Manufactured Aluminium Parts by Modulated Laser Power.
- Author
-
Hofele M, Roth A, Schanz J, Neuer J, Harrison DK, De Silva AKM, and Riegel H
- Abstract
In this study a new approach to laser polishing with periodic modulated laser power in the kilohertz regime is introduced. By varying the modulation frequency and modulation time, different periodic laser power curves with varying minimum, peak and average laser power can be created. The feasibility of the method is shown by polishing of vertical built AlSi10Mg L-PBF parts with an initial roughness of Ra = 12.22 µm. One polishing pass revealed a decreasing surface roughness with increasing energy density on the surface up to Ra = 0.145 µm. An increasing energy density results in a rising remelting depth between 50 and 255 µm and a rising relative porosity of 0.3% to 4.6%. Furthermore, the thermal process stability, analysed by the melt pool length in scanning direction, reveals a steadily increasing melt pool dimension due to component heating. Multiple laser polishing passes offers a further reduced surface roughness, especially at higher modulation frequencies and provides an improved orientation independent roughness homogeneity. The process stability regarding varying initial surface roughness revealed an almost constant relative roughness reduction rate with an achievable roughness variation after two polishing passes between Ra = 0.13-0.26 µm from an initial state of Ra = 8.0-19.2 µm.
- Published
- 2021
- Full Text
- View/download PDF
47. Additive Manufacturing of Bulk Nanocrystalline FeNdB Based Permanent Magnets.
- Author
-
Goll D, Trauter F, Bernthaler T, Schanz J, Riegel H, and Schneider G
- Abstract
Lab scale additive manufacturing of Fe-Nd-B based powders was performed to realize bulk nanocrystalline Fe-Nd-B based permanent magnets. For fabrication a special inert gas process chamber for laser powder bed fusion was used. Inspired by the nanocrystalline ribbon structures, well-known from melt-spinning, the concept was successfully transferred to the additive manufactured parts. For example, for Nd16.5-Pr1.5-Zr2.6-Ti2.5-Co2.2-Fe65.9-B8.8 (excess rare earth (RE) = Nd, Pr; the amount of additives was chosen following Magnequench (MQ) powder composition) a maximum coercivity of µ
0 Hc = 1.16 T, remanence Jr = 0.58 T and maximum energy density of ( BH )max = 62.3 kJ/m3 have been achieved. The most important prerequisite to develop nanocrystalline printed parts with good magnetic properties is to enable rapid solidification during selective laser melting. This is made possible by a shallow melt pool during laser melting. Melt pool depths as low as 20 to 40 µm have been achieved. The printed bulk nanocrystalline Fe-Nd-B based permanent magnets have the potential to realize magnets known so far as polymer bonded magnets without polymer.- Published
- 2021
- Full Text
- View/download PDF
48. Case Report: Interferon-γ Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome.
- Author
-
Dickel S, Grimm C, Amschler K, Schnitzler SU, Schanz J, Moerer O, Payen D, Tampe B, and Winkler MS
- Subjects
- Humans, Male, Middle Aged, Monocytes pathology, Acquired Immunodeficiency Syndrome drug therapy, Acquired Immunodeficiency Syndrome immunology, Acquired Immunodeficiency Syndrome pathology, COVID-19 immunology, COVID-19 pathology, HLA-DR Antigens immunology, Interferon-gamma administration & dosage, Monocytes immunology, SARS-CoV-2 immunology, Severity of Illness Index, COVID-19 Drug Treatment
- Abstract
Background: The major histocompatibility complex (MHC) class II characterized by monocytes CD14+ expression of human leukocyte antigen receptors (HLA-DR), is essential for the synapse between innate and adaptive immune response in infectious disease. Its reduced expression is associated with a high risk of secondary infections in septic patients and can be safely corrected by Interferon-y (IFNy) injection. Coronavirus disease (COVID-19) induces an alteration of Interferon (IFN) genes expression potentially responsible for the observed low HLA-DR expression in circulating monocytes (mHLA-DR)., Methods: We report a case of one-time INFy injection (100 mcg s.c.) in a superinfected 61-year-old man with COVID-19-associated acute respiratory distress syndrome (ARDS), with monitoring of mHLA-DR expression and clinical tolerance., Observations: Low mHLA-DR pretreatment expression (26.7%) was observed. IFNy therapy leading to a rapid increase in mHLA-DR expression (83.1%)., Conclusions: Severe ARDS in a COVID-19 patient has a deep reduction in mHLA-DR expression concomitantly with secondary infections. The unique IFNy injection was safe and led to a sharp increase in the expression of mHLA-DR. Based on immune and infection monitoring, more cases of severe COVID-19 patients with low mHLA-DR should be treated by IFNy to test the clinical effectiveness., Competing Interests: MW received unrestricted funding from SARTORIUS Ag-Lung research. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Dickel, Grimm, Amschler, Schnitzler, Schanz, Moerer, Payen, Tampe and Winkler.)
- Published
- 2021
- Full Text
- View/download PDF
49. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.
- Author
-
Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, and Bennett JM
- Subjects
- Aged, Congresses as Topic, Female, Humans, Male, Middle Aged, Practice Guidelines as Topic, Leukemia, Myelomonocytic, Chronic diagnosis, Precancerous Conditions diagnosis
- Abstract
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past two decades, our knowledge about the pathogenesis and molecular mechanisms in CMML has increased substantially. In parallel, better diagnostic criteria and therapeutic strategies have been developed. However, many questions remain regarding prognostication and optimal therapy. In addition, there is a need to define potential pre-phases of CMML and special CMML variants, and to separate these entities from each other and from conditions mimicking CMML. To address these unmet needs, an international consensus group met in a Working Conference in August 2018 and discussed open questions and issues around CMML, its variants, and pre-CMML conditions. The outcomes of this meeting are summarized herein and include diag nostic criteria and a proposed classification of pre-CMML conditions as well as refined minimal diagnostic criteria for classical CMML and special CMML variants, including oligomonocytic CMML and CMML associated with systemic mastocytosis. Moreover, we propose diagnostic standards and tools to distinguish between 'normal', pre-CMML and CMML entities. These criteria and standards should facilitate diagnostic and prognostic evaluations in daily practice and clinical studies in applied hematology., (Copyright© 2019 Ferrata Storti Foundation.)
- Published
- 2019
- Full Text
- View/download PDF
50. Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes.
- Author
-
Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, and Haase D
- Subjects
- Cytogenetic Analysis, Humans, Karyotyping, Leukocytes, Mononuclear, Myelodysplastic Syndromes pathology, Antigens, CD34 blood, Bone Marrow Cells pathology, High-Throughput Nucleotide Sequencing methods, Mutation, Myelodysplastic Syndromes genetics
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.